# OnCo record allopurinol (drug). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/drugs/allopurinol/>
  a schema:Drug ;
  onco:kind "drug" ;
  schema:identifier "allopurinol" ;
  schema:name "Allopurinol"@en ;
  schema:alternateName "allopurinol"@en, "allopurinol sodium"@en, "Zyloprim"@en, "Aloprim"@en, "Zyloprim / Aloprim" ;
  schema:description "Allopurinol is a long-established tablet, also given by drip, that lowers the body's production of uric acid. When treatment breaks down a large number of cancer cells quickly, uric acid can build up and harm the kidneys; allopurinol is used to prevent and manage this."@en ;
  schema:url <https://onco.cc/drugs/allopurinol/> ;
  schema:dateModified "2026-11-03"^^xsd:date ;
  schema:citation <https://list.essentialmeds.org/medicines/71>, <https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=10cc918f-aa44-415b-932d-2404695ac449> ;
  onco:status "approved" ;
  onco:tag "universe-gap", "who-eml", "supportive" ;
  onco:modality "Small-molecule xanthine oxidase inhibitor (tablet and injection)" ;
  onco:approval "WHO 2007: Essential Medicines List, supportive medicines for cancer: tumour lysis syndrome", "US 1966: Initial US approval of allopurinol (Aloprim label); the injection is indicated for raised uric acid from cancer therapy in leukaemia, lymphoma and solid tumours when oral therapy is not tolerated" ;
  onco:related <https://onco.cc/drugs/rasburicase/> ;
  onco:targets <https://onco.cc/targets/xdh/> ;
  onco:terms <https://onco.cc/terms/tumor-lysis-syndrome/> .